15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering CONMED Corporation, 0 rate it Buy or better, 5 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $36.00 to $46.00, so the covering firms are broadly aligned. The average target of $41.40 sits 11% below the current $46.61. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.27 next quarter toward $4.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Hold
Strong Buy00%
Buy00%
Hold583%
Sell117%
Strong Sell00%
Based on 6 analysts giving stock ratings to CONMED Corporation.
As of Sep, 0 of 6 firms rate CNMD a Buy (5 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
CNMD EPS & revenue forecast
EPS · NEXT QUARTER
$1.27
Range $1.24 – $1.28 · 7 analysts · -12% YoY
Next period, 7 analysts expect CONMED Corporation to earn $1.27 a share (range $1.24 – $1.28), versus $1.43 a year earlier. Full-year consensus is $4.54, growing to $4.78 the year after.
REVENUE · NEXT QUARTER
$369.0M
Range $367.0M – $371.6M · 7 analysts · -1% YoY
Revenue is expected to reach $369.0M (range $367.0M – $371.6M), -1.1% year-over-year. Full-year consensus is $1.4B, rising to $1.4B next year.
Top analysts covering CONMED Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CNMD.
#1
Mike Matson
Needham · Rank #210
Hold
No targeton CNMD
Overall win rate
34%
+ Follow
#2
Matt O'Brien
Piper Sandler · Rank #424
Hold
$45.00-3.5% to target
Overall win rate
25%
+ Follow
#3
LB
Larry Biegelsen
Wells Fargo
Hold
$46.00-1.3% to target
Coverage
—
+ Follow
#4
TS
Travis Steed
B of A Securities
Sell
$40.00-14.2% to target
Coverage
—
+ Follow
#5
Robbie Marcus
JP Morgan
Hold
$40.00-14.2% to target
Coverage
—
+ Follow
CNMD stock forecast FAQ
What is CNMD's average 12-month price target?+
The 4 analysts with a live target average $41.40 for CONMED Corporation over the next 12 months, ranging from a $46.00 high to a $36.00 low.
Is CNMD stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 6 analyst ratings, 0 are Buy or Strong Buy, 5 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for CNMD?+
The Street-high target is $46.00 (Wells Fargo), and the Street-low is $36.00. The average of all 4 active targets is $41.40.
How many Wall Street analysts cover CNMD?+
6 analysts have an active rating on CONMED Corporation, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering CNMD?+
Among analysts who currently cover CNMD, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #210). Their current call is Hold.
What is CONMED Corporation's projected EPS for next quarter?+
The consensus estimate is $1.27 per share (range $1.24 – $1.28) across 7 analysts. Full-year EPS is projected at $4.54, rising to $4.78 the following year.
How much revenue is CONMED Corporation expected to report next quarter?+
Consensus revenue is $369.0M (range $367.0M – $371.6M). Full-year revenue is projected at $1.4B, growing to $1.4B next year.
Have analysts been upgrading or downgrading CNMD lately?+
As of Sep, 0 of 6 firms rate CNMD a Buy (5 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CNMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
